Clinical Trial Update: Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update on LMP744, an indenoisoquinolone Topoisomerase I inhibitor, being studied for recurrent glioblastoma (including IDH-wildtype), in Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioblastoma Idh-wildtype

Drugs mentioned

• LMP744 (indenoisoquinoline topoisomerase I inhibitor)

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING